Regulatory standard

What Does “Essentially a Copy” Mean in Compounding?

503A/503B concepts; clinical difference; shortage context; enforcement; legal uncertainty.

What is established about 503a/503b concepts?

For essentially a copy compounded drug, 503a/503b concepts is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where 503a/503b concepts has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about clinical difference?

For essentially a copy compounded drug, clinical difference is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where clinical difference has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about shortage context?

For essentially a copy compounded drug, shortage context is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where shortage context has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about enforcement?

For essentially a copy compounded drug, enforcement is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where enforcement has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about legal uncertainty?

For essentially a copy compounded drug, legal uncertainty is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where legal uncertainty has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What does this page establish?

It establishes the framework and the source map for essentially a copy compounded drug, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.

What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.

Status terms on this page follow the platform's published status vocabulary.

Why essentially a copy compounded drug is hard to verify

Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.

First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.

That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.

What makes a compounded drug 'essentially a copy'?

This is the doctrine that closed the compounded GLP-1 market, and it is worth understanding precisely because it is frequently described loosely.

The restriction exists to protect the drug approval system. If a compounder could freely reproduce an approved drug, the incentive to run trials and seek approval would collapse. So both section 503A and section 503B restrict compounding a product that is essentially a copy of one commercially available.

The word doing the work is 'commercially available'. While a drug is on the FDA shortage list it is, by definition, not adequately available — and the restriction lifts. That is the entire legal basis on which compounded semaglutide and tirzepatide were supplied, and it is why resolving the shortages ended the market rather than merely regulating it.

Do small changes make a preparation not a copy?

This is the live question. After the shortages resolved, some sellers continued supplying compounded GLP-1 preparations on the argument that adding an ingredient — vitamin B12 is the common example — or varying the dose slightly produces something that is not a copy.

FDA has treated preparations within a narrow range of the approved dose as essentially copies regardless of such additions. The reasoning is straightforward: if a trivial change defeated the restriction, the restriction would mean nothing.

For a buyer the legal argument matters less than two practical facts. A 'personalised' label establishes neither lawful supply nor product quality. And no randomised trial has evaluated any compounded GLP-1 preparation, personalised or otherwise — every efficacy figure in circulation belongs to the approved product.

What this currently costs

Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.

Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.

The multi-dose vial failure mode

An approved pen or single-dose vial removes measurement from the patient entirely. A compounded multi-dose vial reintroduces it, and the reported errors are not small — dosing mistakes by a factor of ten have been documented where a patient or clinician drew the wrong volume.

FDA received more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide as of early 2025, with dosing errors from multi-dose vials a recurring cause and some requiring hospitalisation.

This is the strongest practical argument for approved presentations that has nothing to do with the regulatory argument: removing a calculation step removes a category of error.

Related records in this section

Section hub: Regulatory standards · Methodology · Status definitions · Right to respond

Sources

• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration
• FDA — Registered Outsourcing Facilities
• FDA — Aligning Federal and State Regulation of Compounders
• FDA — Outsourcing Facility Fees
• FDA — Compounded Drug Products That Are Essentially Copies
• FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
• FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
• Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
• FDA — Outsourcing Facility Fees guidance

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.